1. World Health Organization. Model List of Essential Medicines. Children [Internet]. 2010;1–43. Available from: http://www.who.int/medicines/organization/par/edl/expcom13/eml13_en.pdf
2. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999;43(7):1533–1541.
3. Dingsdag SA, Hunter N. Metronidazole: An update on metabolism, structure-cytotoxicity and resistance mechanisms. J Antimicrob Chemother 2018;73(2):265–279.
4. Aronoff, Jerod L. Nagel DM. Metronidzole. In: Mandell GL, Bennett JE Dolin R (Ed) Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases; Elsevier Churchill Livin-
gstone, 2010;419-426. 2020. p. 350–358.
5. Soares GMS, Figueiredo LC, Faveri M, Cortelli SC, Duarte PM, Feres M. Mechanisms of action of systemic antibiotics used in periodontal treatment and mechanisms of bacterial resistance
to these drugs. J Appl Oral Sci 2012;20(3):295–305.
6. Brook I. Spectrum and treatment of anaerobic infections. J Infect Chemother 2016;22(1):1–13.
7. Erwin ME, Fix AM, Jones RN. Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates. Diagn
Microbiol Infect Dis 2001;39(2):129–132.
8. Ardila CM, López MA, Guzmán IC. High resistance against clindamycin, metronidazole and amoxicillin in Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans isolates
of periodontal disease. Med Oral Patol Oral Cir Bucal 2010;15(6).
9. Boyanova L, Hadzhiyski P, Gergova R, Markovska R. Evolution of Helicobacter pylori Resistance to Antibiotics: A Topic of Increasing Concern. Antibiotics 2023;12(2).
10. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization
Regions. Gastroenterology 2018;155(5):1372-1382.e17.
11. Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: A systematic
review and meta-analysis. Antimicrob Resist Infect Control 2020;9(1):1–11.
12. Brook I. Antimicrobial treatment of anaerobic infections. Expert Opin Pharmacother 2011;12(11):1691–1707.
13. Brook I. Antimicrobials therapy of anaerobic infections. J Chemother 2016;28(3):143–150.
14. Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, López Contreras L. Therapeutic uses of metronidazole and its side effects: An update. Eur Rev Med Pharmacol Sci
2019;23(1):397–401.
15. Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50(SUPP.1).
16. Becker E, Schmidt TSB, Bengs S, Poveda L, Opitz L, Atrott K, et al. Effects of oral antibiotics and isotretinoin on the murine gut microbiota. Int J Antimicrob Agents 2017;50(3):342–351.
17. Huang C, Feng S, Huo F, Liu H. Effects of Four Antibiotics on the Diversity of the Intestinal Microbiota. Microbiol Spectr 2022;10(2).
18. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J Infect 2019;79(6):471–489.
19. Leitsch D. A review on metronidazole: An old warhorse in antimicrobial chemotherapy. Parasitology 2019;146(9):1167–1178.
20. Ingham HR, Eaton S, Venables CW, Adams PC. Bacteroides Fragilis Resistant To Metronidazole After Long-Term Therapy. Lancet 1978;311(8057):214.
21. Doron SI, Beaulac KR, Dhand A, Snydman DR. Mechanisms of Resistance in Metronidazole. Antimicrob Drug Resist 2017;281–287.
22. O’Grady K, Knight DR, Riley T V. Antimicrobial resistance in Clostridioides difficile. Eur J Clin Microbiol Infect Dis 2021;40(12):2459–2478.
23. Husen O, Aliyo A, Boru K, Gemechu T, Dedecha W, Ashenafi G. Trichomonas vaginalis and Associated Factors among Pregnant Women Attending Antenatal Care at Bule Hora University
Teaching Hospital, Oromia Region, Southern Ethiopia. J Parasitol Res 2023;2023.
24. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist. 2012;2:204–215.
25. Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J
Emerg Surg 2021;16(1):1–48.
26. Sobel R, Sobel JD. Metronidazole for the treatment of vaginal infections. Expert Opin Pharmacother 2015;16(7):1109–1115.
27. Vely AP, Ferrada P. Clostridium difficile infection. Emerg Gen Surg A Pract Approach 2018;(xx):277–281.
28. Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile infection. Emerg Infect 10. 2016;265–294.
29. Kaplan M. Helicobacter Pylori Treatment in Turkey: Current Status and Rational Treatment Options. North Clin Istanbul 2019;7(1):87–94.
30. McClellan KJ, Noble S. Topical metronidazole: A review of its use in Rosacea. Am J Clin Dermatol 2000;1(3):191–199.
31. de Castro DLV, Santos VLC de G. Controlling wound odor with metronidazole: A systematic review. Rev da Esc Enferm 2015;49(5):858–863.
32. Lyvers E, Elliott DP. Topical metronidazole for odor control in pressure ulcers. Consult Pharm 2015;30(9):523–526.
33. Ring HC, Knudsen A, Thomsen SF. Metronidazole for Hidradenitis Suppurativa: future potential treatment applications. J Eur Acad Dermatology Venereol 2021;35(5):e323–324.
34. Augustín-Bandera V, Aguilar-García JA, Aparicio-Camberos J, Romero-Gómez C. Neurotoxicity induced by metronidazole. Neurologia 2020;35(9):655–657.
35. Qian C, Abourizk N, Rizk MA, Kim J, Smith DL, Westra KC, et al. A rare case of metronidazole induced recurrent pancreatitis. Pancreatology 2021;21(1):318–319.
36. Hosack T, Mandal AKJ, Griffiths C, Missouris CG. Idiosyncratic metronidazole-induced neutropaenia in an older adult. Br J Hosp Med 2023;84(6):2021–2024.
37. Adil M, Iqbal W, Adnan F, Wazir S, Khan I, Khayam MU, et al. Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions? Curr Drug Metab
2018;19(11):902–909.
38. Dobiáš L, Černá M, Rössner P, Šrám R. Genotoxicity and carcinogenicity of metronidazole. Mutat Res Genet Toxicol 1994;317(3):177–194.
39. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36(5):353–373.
40. Miljkovic V, Arsic B, Bojanic Z, Nikolic G, Nikolic LJ, Kalicanin B, et al. Interactions of metronidazole with other medicines: A brief review. Pharmazie 2014;69(8):571–577